Immunohistochemical Expression of Somatostatin Receptors 1, 2, 3, and 5 Types (SSR) in Functioning and Non-Functioning Gastroenteropancreatic Neuroendocrine Tumors

#689

Introduction: SSRs are therapeutic targets for the somatostatin analogues in treatment of gasrtroenteropancreatic neuroendocrine tumors (GEP-NET).

Aim(s): To compare the expression rate of SSR types 1-3, 5 in different grade and localization GEP-NETs

Materials and methods: We examined immunohistochemicaly the expression of SSR1-3,5 in 126 GEP-NETs: 86 tumors of the pancreas (pNET), 40 of the intestine (inNET), 89 NET were functioning. To determine the SSR2,5 rabbit monoclonal antibodies were used. We considered expression of SSRs with an intensity of 2-3+ in not less than 50% of tumor cells

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Gurevich L, Kazantseva I, Panteleeva E, Britvin T, Egorov A,

Keywords: neuroendocrine, tumors, somatostatin, receptor,